EGFR and non-small cell lung carcinoma: (42) revealed that unlike with erlotinib or gefitinib, the clinical benefit of first-line osimertinib treatment in NSCLC patients with EGFR mutations was unaffected by PD-L1 expression status (PFS: PD-L1-positive (TC ≥1%) vs. PD-L1-negative patients (TC <1%): 18.4 vs. 18.9 months).